Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...

Significant associations for semaglutide initiation included being female, using certain medication classes including antidepressants, and being covered by a point-of-service plan. (HealthDay News ...

Female sex, antidepressant use, and type of health insurance significantly influence semaglutide initiation. (HealthDay News) — Sociodemographic, health care, and clinical factors are associated ...